Kosiborod M, et al. - The tie-up between initiation of sodium-glucose co-transporter-2 inhibitors (SGLT-2i) vs other glucose-lowering drugs (oGLDs) and rates of myocardial infarction (MI) and stroke were investigated by the experts. Medical records, claims and national registers from the USA, Sweden, Norway and Denmark assisted in selecting patients with T2D who newly initiated treatment with SGLT-2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs. Initiation of SGLT-2i vs oGLD exhibited a connection with a modestly lower risk of MI and stroke. Obtained data complemented the results of the cardiovascular outcomes trials. Additional reassurance in terms of the cardiovascular effects of SGLT-2i was gained, specifically since it associated with ischaemic events.